How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?

How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?
·4 min read

Moderna (NASDAQ: MRNA) currently has one product on the market -- its COVID-19 vaccine -- which will probably generate sales in the ballpark of $20 billion for the company this year. Pfizer (NYSE: PFE) is Moderna's chief rival in the COVID-19 vaccine market. Now for the shocker: Moderna's market cap currently is close to $127 billion, while Pfizer's market cap stands near $230 billion.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting